ReViral announces Series B investment ReViral announces US$55 million series B fundraising to advance RSV clinical studies London, UK – 1st August 2018: ReViral, an antiviral drug discovery and development company, focused on diseases caused by the Respiratory...
Neuronetics, Inc., Maker of NeuroStar® Advanced Therapy, Announces Pricing of Initial Public Offering MALVERN, Pa., June 28, 2018 (GLOBE NEWSWIRE) — Neuronetics, Inc., a commercial-stage medical device company focused on designing, developing, and manufacturing...
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock WALTHAM, Mass.–(BUSINESS WIRE)–Jun. 11, 2018– Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key...
Iterum Therapeutics Announces Pricing of Initial Public Offering DUBLIN and CHICAGO, May 24, 2018 /PRNewswire/ — Iterum Therapeutics plc (NASDAQ:ITRM), a clinical-stage pharmaceutical company developing anti-infectives aimed at combatting the global crisis of...
Truveris Expands Audit Capabilities with Launch of TruAudit™ Solution allows clients to track PBM performance by implementing several new audits NEW YORK–(BUSINESS WIRE)–Truveris, Inc. today announced new audit capabilities geared towards further...
Recent Comments